股市必读：山东药玻（600529）1月14日主力资金净流入964.26万元，占总成交额1.5%

Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. plans to issue up to 199,084,233 A-shares at a price of 16.25 yuan per share, aiming to raise no more than 3.235 billion yuan to supplement working capital, with a change in control to China National Pharmaceutical Group Corporation [2][4][6] Trading Information Summary - As of January 14, 2026, Shandong Pharmaceutical Glass closed at 21.0 yuan, up 2.24%, with a turnover rate of 4.63%, trading volume of 307,500 shares, and a transaction amount of 645 million yuan [1] - On the same day, the net inflow of main funds was 9.6426 million yuan, accounting for 1.5% of the total transaction amount, while retail investors had a net outflow of 1.5527 million yuan, accounting for 0.24% [2] Company Announcement Summary - The company’s board approved a proposal to issue shares to specific entities, which requires further approval from the shareholders' meeting, state-owned asset regulatory authorities, the Shanghai Stock Exchange, and the China Securities Regulatory Commission [2][4] - The issuance will result in a change of control, with China National Pharmaceutical Group becoming the actual controller, and the original controlling shareholder, Luzhong Investment, terminating its cooperation with China National Pharmaceutical International on January 11, 2026 [3][6] - The company has committed not to provide financial assistance or guarantees to the issuing entities and has acknowledged the potential dilution of immediate returns from this issuance [4][5] Financial and Operational Insights - The company’s previous fundraising net amount was approximately 1.842 billion yuan, with 1.141 billion yuan invested by September 30, 2025, and the investment progress is reported as normal [4][5] - The company expects to have daily related transactions with China National Pharmaceutical Group totaling 46.7 million yuan in 2026, primarily for the sale of pharmaceutical glass packaging materials [5] - The feasibility analysis report indicates that the raised funds will be used entirely to supplement working capital, enhancing capital strength, research innovation capabilities, and risk resistance [5][6]